

# Press Release

Malmö, SWEDEN – October 17, 2007

## Hansa Medical listed on First North

Trading of the Hansa Medical share will commence today, October 17, 2007, on First North under the ticker symbol HMED. One trading unit comprises 500 shares. Hansa Medical's certified adviser is Kaupthing Bank.

In September and October, Hansa Medical successfully implemented a new share issue targeting the general public, comprising 3.8 million shares at an issue price of SEK 10. The issue, which generated considerable interest, was fully subscribed and enabled Hansa Medical to raise SEK 38 M before issue expenses. The proceeds of the issue will be used to finance a clinical development plan for Hansa Medical's lead project, IdeS, and key investments in two smaller projects. The number of shares in Hansa Medical is 3,924,714, of which 36 percent is owned by the company's Chairman of the Board, Bo Håkansson, through a holding company. Hansa Medical Board members Stina Gestrelus and Per Belfrage, CEO Emanuel Björne, Project Manager Anita Tocaj and research partner Professor Lars Björck are also shareholders in Hansa Medical.

### About First North

First North is an alternative marketplace for small growth companies that provides visibility and ease of access to northern Europe's capital market. First North is part of the OMX Nordic Exchange Stockholm.

For more information, please contact:

### Emanuel Björne, CEO

Telephone: +46 40 630 76 04

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

### ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including diagnostics and drugs for sepsis.

Hansa Medical AB  
CRC Entrance 72  
UMAS  
SE-205 02 Malmö, Sweden  
TELEPHONE +46 40 630 76 04  
FAX +46 40 23 93 10

[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

VISITING ADDRESS:  
Clinical Research Centre at  
Malmö University Hospital  
Entrance 72  
Malmö, Sweden